News

Teva’s Synribo approved for home administration

BY Ryan Chavis

JERUSALEM — Teva Pharmaceutical Industries on Monday announced that the Food and Drug Administration approved Synribo (omacetaxine mepesuccinate) for injection, to include home administration. With the announcement of the approval, physicians who treat adults with chronic or accelerated phase CML (who are no longer responding to or can’t tolerate  two or more tyrosine kinase inhibitors) now have the option to allow patients to administer Synribo at home.

“As we continue to expand our oncology portfolio and services at Teva, the updated labeling for Synribo demonstrates our commitment to improving the overall experience and lowering barriers to treatment for people living with CML,” said Bill Campbell, VP and general manager, Teva Oncology. “Home administration can reduce the number of required doctor office visits for patients being treated with Synribo, while still maintaining close collaboration with their healthcare provider to manage their treatment regimen.”

Teva is finalizing a comprehensive specialty pharmacy support program, which will help facilitate home administration of Synribo for HCPs, their patients and caregivers. It’s expected to "go live" in the second quarter of 2014.  

“As an oncology nurse practitioner who has treated CML patients for nearly 20 years, I’m thrilled to see this unique therapy become available for home administration,” said Sandra Corbin, CRNP at Calvert Hematology and Oncology. “Patients may initially express concern at the thought of self-injecting — but with training and support, most can become skilled at administering the subcutaneous injections.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Walgreens posts 8.8% boost in April sales

BY Antoinette Alexander

DEERFIELD, Ill. — Walgreens posted April sales of $6.49 billion, an increase of 8.8% from $5.96 billion for the same month in fiscal 2013.

Total front-end sales increased 8.8% in April compared with the same month in fiscal 2013, while same-store front-end sales increased 8.2%. Customer traffic in comparable stores increased 2.6% while basket size increased 5.6%.

For the combined March/April period that includes the Easter holiday season impact, comparable store front-end sales increased by 2.1%, while customer traffic in comparable stores decreased 0.9% and basket size increased 3%.

Prescriptions filled at comparable stores increased by 3.5% in April and increased 4.3% on a calendar day-shift adjusted basis. April 2014 had one additional Wednesday and one fewer Monday compared with April 2013. The retailer noted that the calendar shifts negatively impacted prescriptions filled at comparable stores by 0.8 percentage point.

April pharmacy sales increased by 9.2%. Comparable store pharmacy sales increased 7.3% and increased by a calendar day-shift adjusted 8.1%. Calendar day shifts negatively impacted pharmacy sales in comparable stores by 0.8 percentage point. Calendar day-shift adjusted comparable store pharmacy sales were negatively impacted by 1.3 percentage points due to generic drug introductions in the last 12 months. Pharmacy sales accounted for 64.5% of total sales for the month, the company stated.

Sales in comparable stores increased by 7.6% in April. Calendar day shifts negatively impacted total comparable sales by 0.5 percentage point. Generic drug introductions in the last 12 months negatively impacted total comparable sales by 0.8 percentage point.

Sales for the combined months of March and April 2014 increased 6.6% from the same two months in 2013. Comparable store sales for the March/April period increased 5.5%.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Kmart working with Diplomat Specialty Pharmacy to offer specialty meds

BY Antoinette Alexander

HOFFMAN ESTATES, Ill. — Kmart Pharmacy has announced that it is working with Diplomat Specialty Pharmacy to give Kmart customers and Shop Your Way members access to specialty medications.

By 2018, specialty medications are projected to account for more than 51% of sales within the top 100 prescription products. Through this new agreement with Diplomat Pharmacy, Kmart is looking to offer a new level of service and convenience to meet the needs of the growing specialty medication population. 
 

“We understand that when patients are dealing with a chronic or complex health condition they need an extra level of care,” stated Mark Panzer, president of Pharmacy for Sears Holdings. “By partnering with Diplomat Pharmacy, Kmart Pharmacy is able to provide a highly trained team to support medication therapy and comprehensive care management to better serve our specialty pharmacy members.”
 

In addition to HIV, Crohn’s, anemia and Hepatitis C, Kmart Pharmacies will also offer specialty medications to treat conditions such as cystic fibrosis, growth hormone, multiple sclerosis, osteoporosis, renal, rheumatoid arthritis, and transplants. In addition, patients will have access to patient care coordinators familiar with their medical files, specialized injection training (for patients requiring this service), and manufacturer co-payment support cards for eligible patients.
 

“Working with Kmart Pharmacies means millions more will have access to specialty drugs through the convenience of their local Kmart pharmacy,” stated Ela Lourido, director of Retail Specialty Network for Diplomat. “It also means patients will have access to teams of specialists who understand their unique needs. The big winner in this is the specialty drug patient who now has a full team of healthcare professionals at their disposal, working together to ensure the best outcome.”

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES